Jun Yasuhara MD, PhD , Mona Aljuhani PhD , Talita Z. Choudhury PhD , Anupama Rao PhD , Sara Conroy PhD , Yukie Ueyama DVM , Stephanie LaHaye PhD , Karlee Schultz MS , Emily M. Cameron MS , Sathiya N. Manivannan PhD , Uddalak Majumdar PhD , Vidu Garg MD
{"title":"Disruption of Notch1 and Gata5 in Mice Leads to Congenital Aortic Valve Disease","authors":"Jun Yasuhara MD, PhD , Mona Aljuhani PhD , Talita Z. Choudhury PhD , Anupama Rao PhD , Sara Conroy PhD , Yukie Ueyama DVM , Stephanie LaHaye PhD , Karlee Schultz MS , Emily M. Cameron MS , Sathiya N. Manivannan PhD , Uddalak Majumdar PhD , Vidu Garg MD","doi":"10.1016/j.jacbts.2025.101354","DOIUrl":"10.1016/j.jacbts.2025.101354","url":null,"abstract":"<div><div>Here, we describe <em>Notch1;Gata5</em> compound mutant mice as a novel mouse model of highly penetrant congenital aortic valve disease displaying bicuspid aortic valve and progressive aortic valve stenosis. Further, we find downregulation of smooth muscle genes in the neonatal aortic valves in <em>Notch1;Gata5</em> compound mice consistent with an immature valve phenotype. Our findings demonstrate a novel genetic interaction between <em>Notch1</em> and <em>Gata5</em> in mice that is critical for proper aortic valve development. This novel model is an important tool to define dysregulated signaling pathways for congenital aortic valve stenosis and stenotic disease progression that can be investigated as therapeutic targets.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 9","pages":"Article 101354"},"PeriodicalIF":8.4,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Imran Aslam MD , Aleksandra B. Gruslova PhD , Luis A. Diaz Sanmartin MS , Drew Nolen MS , James J. Elliott DVM , Alexander J. Moody PhD , Joel E. Michalek PhD , Vivek P. Jani BS, MS , Fawaz Alenezi MD, MSc , Clay Heighten MD , Jonathan W. Valvano PhD , Marc D. Feldman MD
{"title":"An Integrated Pressure-Volume Loop and Pulmonary Artery Catheter","authors":"M. Imran Aslam MD , Aleksandra B. Gruslova PhD , Luis A. Diaz Sanmartin MS , Drew Nolen MS , James J. Elliott DVM , Alexander J. Moody PhD , Joel E. Michalek PhD , Vivek P. Jani BS, MS , Fawaz Alenezi MD, MSc , Clay Heighten MD , Jonathan W. Valvano PhD , Marc D. Feldman MD","doi":"10.1016/j.jacbts.2025.101326","DOIUrl":"10.1016/j.jacbts.2025.101326","url":null,"abstract":"<div><div>An admittance technology (AT) pulmonary artery catheter was developed to measure instantaneous right ventricular (RV) pressure-volume loops. Admittance RV volumes were validated in vivo through 10 swine subjected to positive and negative hemodynamic perturbations compared with magnetic resonance imaging and ex vivo RV foam casts. Finite element analysis demonstrated the AT electric field was confined to RV blood volume. RV pressure-volume loops demonstrated anticipated changes in all hemodynamics, and end-diastolic volumes were equal to magnetic resonance imaging and foam casts (<em>P =</em> NS). Increasing RV end-diastolic volumes in response to acute cardiac injury were also measured (<em>P <</em> 0.001). We report validating an AT pulmonary artery catheter in a swine model.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101326"},"PeriodicalIF":8.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144724255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W.H. Wilson Tang MD , Johannes Steiner MD , Mahwash Kassi MD , Matthew T. Wheeler MD , Aferdita Spahillari MD, MPH , Nancy K. Sweitzer MD, PhD , Justin L. Grodin MD, MPH , Neal Solomon MD , Shalabh Singhal MD , Amanda M.G. McEwen MS , Samuel L. Murphy MD
{"title":"Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction","authors":"W.H. Wilson Tang MD , Johannes Steiner MD , Mahwash Kassi MD , Matthew T. Wheeler MD , Aferdita Spahillari MD, MPH , Nancy K. Sweitzer MD, PhD , Justin L. Grodin MD, MPH , Neal Solomon MD , Shalabh Singhal MD , Amanda M.G. McEwen MS , Samuel L. Murphy MD","doi":"10.1016/j.jacbts.2025.101352","DOIUrl":"10.1016/j.jacbts.2025.101352","url":null,"abstract":"<div><div>This first-in-human, phase 1, double-blind, placebo-controlled study evaluated the safety, tolerability, immunogenicity, pharmacokinetics, and exploratory efficacy of a selective ErbB4 agonist, JK07, in patients with heart failure with reduced ejection fraction (HFrEF). In these patients on optimal goal-directed medical therapy, JK07 was generally safe and well tolerated at dose levels up to 0.09 mg/kg. There was a trend toward increased incidence and severity of treatment-emergent adverse events observed at the highest dose of 0.27 mg/kg. Consistent with prolonged effects seen with transient exposure to neuregulin-1 in previous phase 1 investigations, improvements in left ventricular ejection fraction lasting up to 180 days after infusion were observed. These findings support continued clinical investigation of JK07 in heart failure. (Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction; <span><span>NCT04210375</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 9","pages":"Article 101352"},"PeriodicalIF":8.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alwin de Jong MD, PhD , Thijs J. Sluiter BSc , Hendrika A.B. Peters BSc , Alec Lamens MSc , J. Wouter Jukema MD, PhD , Ramon Arens PhD , Paul.H.A. Quax PhD , Margreet R. de Vries PhD
{"title":"CD137 Signaling Modulates Vein Graft Atherosclerosis by Driving T-Cell Activation and Regulating Intraplaque Angiogenesis","authors":"Alwin de Jong MD, PhD , Thijs J. Sluiter BSc , Hendrika A.B. Peters BSc , Alec Lamens MSc , J. Wouter Jukema MD, PhD , Ramon Arens PhD , Paul.H.A. Quax PhD , Margreet R. de Vries PhD","doi":"10.1016/j.jacbts.2025.101323","DOIUrl":"10.1016/j.jacbts.2025.101323","url":null,"abstract":"<div><div>Atherosclerotic vein graft failure still presents a major problem. T-cells have been identified as one of the most abundant immune cell subset in atherosclerotic plaques. Their role, however, remains only partly understood. Using a murine vein graft model for advanced, unstable atherosclerotic lesions, we find that T-cells accumulate over time in atherosclerotic vein grafts, and appear to be activated rapidly after engraftment, demonstrated by increased expression of CD137 on plaque T-cells. Targeting of CD137 affects intraplaque angiogenesis and plaque growth, which renders CD137 a promising target for early immunomodulation to reduce atherosclerotic vein graft failure.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101323"},"PeriodicalIF":8.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144724254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natalia Matiuto BS , Brandon Applewhite PhD , Nicola Habash BS , Ana Martins MS , Bowen Wang PhD , Bin Jiang PhD
{"title":"Harnessing Mitochondrial Transplantation to Target Vascular Inflammation in Cardiovascular Health","authors":"Natalia Matiuto BS , Brandon Applewhite PhD , Nicola Habash BS , Ana Martins MS , Bowen Wang PhD , Bin Jiang PhD","doi":"10.1016/j.jacbts.2025.101331","DOIUrl":"10.1016/j.jacbts.2025.101331","url":null,"abstract":"<div><div>Mitochondrial dysfunction is a key contributor to vascular inflammation in many cardiovascular diseases. This review explores mitochondrial transplantation as a promising strategy for addressing mitochondrial dysfunction and vascular inflammation. We discuss mitochondrial dysfunction across different vascular cell types and current clinical management strategies, highlighting the need for novel approaches that directly target mitochondrial health. We also present recent progress in mitochondrial transplantation across cardiac, neurovascular, and peripheral vascular applications in preclinical settings, as well as ongoing clinical trials. Important technical considerations, such as mitochondria sourcing, delivery routes, and storage, are discussed to facilitate future translation. By reinstating mitochondrial health and hence mitigating vascular inflammation, mitochondrial transplantation holds the potential to provide novel, targeted therapies for cardiovascular diseases, ultimately improving patient outcomes, reducing disease progression, and addressing unmet medical needs in vascular health. The translation of this technology into clinical practice could offer significant advances in the treatment of a wide range of cardiovascular conditions.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101331"},"PeriodicalIF":8.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Taiki Hayasaka MD, PhD , Bruno Moukette PhD , Marisa N. Sepúlveda PhD , Satoshi Kawaguchi MD, PhD , Tatsuya Aonuma MD, PhD , Hamedane Moustapha MS , Lei Yang PhD , Meena S. Madhur MD, PhD , Suthat Liangpunsakul MD , Il-man Kim PhD
{"title":"Periostin is a Pivotal Target of microRNA-150-5p in Cardiac Fibroblast Activation and Chronic Myocardial Infarction","authors":"Taiki Hayasaka MD, PhD , Bruno Moukette PhD , Marisa N. Sepúlveda PhD , Satoshi Kawaguchi MD, PhD , Tatsuya Aonuma MD, PhD , Hamedane Moustapha MS , Lei Yang PhD , Meena S. Madhur MD, PhD , Suthat Liangpunsakul MD , Il-man Kim PhD","doi":"10.1016/j.jacbts.2025.101330","DOIUrl":"10.1016/j.jacbts.2025.101330","url":null,"abstract":"<div><div>Our prior studies have revealed that miR-150-5p (miR-150) attenuated cardiac dysfunction in mice, which overexpressed a long noncoding RNA called myocardial infarction–associated transcript during myocardial infarction or harbored cardiac-specific abrogation of β-arrestin–mediated β<sub>1</sub>-adrenergic receptor signaling during chronic catecholamine stimulation. Although previous studies have shown the importance of miR-150 in heart failure, details surrounding its actions remain elusive in part because of (1) the lack of detailed mechanistic insight by which this small noncoding RNA induces myocardial protection and (2) the absence of definitive studies using appropriate mouse models to establish its direct functional relationship with key downstream targets. In the current study, we provide strong evidence that fibrotic periostin is a significant downstream target of miR-150 repression in ischemic mouse hearts. To the best of our knowledge, this is the first study to directly establish the functional link between miR-150 and periostin in murine myocardial infarction and primary adult human cardiac fibroblast activation.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101330"},"PeriodicalIF":8.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ufmylation-Mediated Unfolded Protein Response as An Innovative Therapeutic Target in Peripartum Cardiomyopathy.","authors":"Debabrata Chowdhury, Guo-Chang Fan","doi":"10.1016/j.jacbts.2025.101332","DOIUrl":"https://doi.org/10.1016/j.jacbts.2025.101332","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":" ","pages":"101332"},"PeriodicalIF":8.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhuofan Li BS , Ze Gong PhD , Weihao Li MD , Yanghui Chen PhD , Rongbo Dai PhD , Shiyu Yang BS , Yufei Chen PhD , Fang Yu MS , Yi Fu MBBS, PhD , Wei Li MD , Dao Wen Wang MD, PhD , Yiting Jia PhD , Wei Kong MD, PhD
{"title":"The Reduction of COMP Serves as a Predictor for Warning of Aortic Dissection Progression","authors":"Zhuofan Li BS , Ze Gong PhD , Weihao Li MD , Yanghui Chen PhD , Rongbo Dai PhD , Shiyu Yang BS , Yufei Chen PhD , Fang Yu MS , Yi Fu MBBS, PhD , Wei Li MD , Dao Wen Wang MD, PhD , Yiting Jia PhD , Wei Kong MD, PhD","doi":"10.1016/j.jacbts.2025.101329","DOIUrl":"10.1016/j.jacbts.2025.101329","url":null,"abstract":"<div><div>Thoracic aortic dissection (TAD) is a life-threatening cardiovascular disease that is associated with high morbidity and mortality. The prevailing challenge in TAD monitoring and diagnosis is the lack of novel biomarkers. A significant and sustained reduction in plasma cartilage oligomeric matrix protein (COMP) levels was observed through a case control analysis conducted in 362 TAD patients and 136 controls. The protective role of COMP was assessed in two TAD mouse models. These data suggested that a decreased plasma COMP level might serve as a novel biomarker for TAD progression and COMP could suppress the development of TAD and ameliorate vascular pathogenesis.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101329"},"PeriodicalIF":8.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}